• Psyence BioMed began dosing patients in Phase IIb trial of NPX-5, a 25 mg nature-derived psilocybin candidate, for adjustment disorder in cancer patients receiving palliative care.
• No results have been presented; trial is expected to generate safety and efficacy data in a future readout.
• Study aims to assess whether NPX-5 can reduce psychological distress while remaining tolerable in this patient group.
• Randomized, double-blind, three-arm design is running across five clinical sites in Australia.
• Program supports Psyence BioMed strategy to build vertically integrated psychedelic drug development platform spanning manufacturing, clinical execution, and supply.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604230700PRIMZONEFULLFEED9695403) on April 23, 2026, and is solely responsible for the information contained therein.